Search

Search Constraints

You searched for: Author/Creator Ceresoli, Giovanni Luca

Search Results

2. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. (February 2020)

3. Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. (August 2019)

4. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10 (October 2021)

10. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. (February 2020)